Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash		$ 4
Restricted cash	240	1,000
Prepaid expenses	802	1,105
Total current assets	1,042	2,109
Investment in Virion	90	3,392
TOTAL ASSETS	1,132	5,501
CURRENT LIABILITIES:
Accounts payable and accrued expenses	16,570	16,185
Short-term loans, net of issuance costs	12,838	12,118
SPA Warrant	3,573	764
Total current liabilities	33,649	30,013
NONCURRENT LIABILITIES
Fixed maturity consideration	5,163	4,123
Backstop put option liability	57,041	58,523
Virion contribution liability	3,364	3,605
Total liabilities	99,217	96,264
STOCKHOLDERS’ DEFICIT:
Common stock, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively, 34,868,628 and 34,649,046 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively.
Additional paid-in capital	107,733	105,292
Accumulated deficit	(205,818)	(196,055)
Total stockholders’ deficit	(98,085)	(90,763)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	1,132	5,501
Related Party [Member]
CURRENT LIABILITIES:
Accrued expenses – related party	$ 668	$ 946